secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001683168-22-001345
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech receives Nasdaq board independence deficiency notice after director death
--------------------------------------------------------------------------------

- Independent director Thomas C.K. Yuen passed away Feb 13, 2022, triggering noncompliance with Nasdaq Listing Rule 5605(b)(1).
- Cure period: until earlier of next annual shareholders' meeting or Feb 13, 2023; if meeting before Aug 12, 2022, compliance by Aug 12, 2022.
- Company expects to appoint a new independent director to regain compliance before the cure period expires.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822001345/0001683168-22-001345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822001345/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-001345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer